The Dutch cancer company, Modra Pharmaceuticals BV, has recruited Colin Freund to be chief executive and help manage its portfolio of re-formulated taxane chemotherapies. Mr Freund was previously CEO of the Australian oncology company QUE Oncology Inc and chief business officer of Transgene SA in France. He received an MA in economics and management studies from the University of Cambridge in the UK and an MBA from Stanford University in the US.
Modra Pharmaceuticals announced the appointment on 19 December 2018.
Copyright 2019 Evernow Publishing Ltd